Tech Company Financing Transactions

Aro Biotherapeutics Funding Round

On 1/6/2021, Aro Biotherapeutics landed $88 million in Series A investment from Cowen Capital Partners, Northpond Ventures and BioMotiv.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

3675 Market St. 200
Philadelphia, PA 19104
USA

Phone

Undisclosed

Website

www.arobiotx.com

Email Address

[email protected]

Overview

Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Susan Dillon

        

Chief Scientific Officer

Karyn O'Neil

        

VP - Administration

Mark Laurenzi

        

VP - Bus. Development

Scott Greenberg

        

VP - R & D

Steven Nadler

        

Browse more venture capital transactions:

Prev: 1/6/2021: Immuneering venture capital transaction
Next: 1/6/2021: Divvy venture capital transaction

Share this article

About Database of VC Transactions

We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary